Oncotarget

Research Papers:

Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes

Xiao-Wei Zhang, Su Mi, Zhe Li, Ji-Chao Zhou, Jing Xie, Fang Hua, Ke Li, Bing Cui, Xiao-Xi Lv, Jiao-Jiao Yu and Zhuo-Wei Hu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9922-9934. https://doi.org/10.18632/oncotarget.14266

Metrics: PDF 2745 views  |   HTML 2686 views  |   ?  


Abstract

Xiao-Wei Zhang1, Su Mi1, Zhe Li1, Ji-Chao Zhou1, Jing Xie1, Fang Hua1, Ke Li2, Bing Cui1, Xiao-Xi Lv1, Jiao-Jiao Yu1, Zhuo-Wei Hu1

1Molecular Immunology and Pharmacology Group, State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Correspondence to:

Zhuo-Wei Hu, email: huzhuowei@imm.ac.cn

Keywords: cirrhosis, inflammation, liver injury, neutralizing antibody, p62

Received: August 23, 2016     Accepted: December 01, 2016     Published: December 27, 2016

ABSTRACT

Interleukin-17A has been identified as a driver of hepatic stellate cell activation and plays a critical role in the pathogenesis of hepatic fibrosis. However, the underlining fibrosis-promoting mechanism of IL-17A is far from understood. Here we aimed to define whether hepatocytes directly respond to IL-17A stimulation and are associated with the development of hepatic fibrosis. The functional significance of IL-17A was evaluated in bile duct ligation (BDL) or thioacetamide (TAA) injection-induced mouse models of hepatic fibrosis. Human cirrhosis and control tissues were obtained from the patients with cirrhosis who received an open surgical repair process. Neutralizing IL-17A promoted the resolution of BDL or TAA-induced acute or chronic inflammation and fibrosis, resulted in a shift of the suppressive immune response in fibrotic liver toward a Th1-type immune response, and restored autophagy activity in both cholestatic and hepatotoxic liver injury induced fibrotic liver tissues, which was accompanied by a significant inhibition of STAT3 phosphorylation. Moreover, we found that IL-17A stimulated the concentration-and time-dependent phosphorylation of STAT3 in AML-12 liver cells. Blocking STAT3 with a specific inhibitor STATTIC or STAT3 siRNA protected from the IL-17A-induced autophagy suppression in AML-12 cells, indicating that STAT3 mediates IL-17A-suppressed autophagy. Administration of IL-10, which activated STAT3 and inhibited autophagy, reversed the therapeutic effect of IL-17A antagonism in vivo. Our study suggests that the IL-17A/STAT3 signaling pathway plays a crucial role in the pathogenesis of hepatic fibrosis through suppressing hepatocellular autophagy and that blocking this pathway may provide therapeutic benefits for the treatment of hepatic fibrosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14266